ARTA
XENE icon

A.R.T. Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

A.R.T. Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,760
Closed -$106K – 1767
2019
Q2 		$106K Buy
+10,760
New +$103K 0.01% 1186
2018
Q3 		– Sell
-11,988
Closed -$110K – 1754
2018
Q2 		$110K Buy
+11,988
New +$74.5K ﹤0.01% 1290
2017
Q3 		– Sell
-15,829
Closed -$49K – 1714
2017
Q2 		$49K Buy
15,829
+3,329
+27% +$13K ﹤0.01% 1306
2017
Q1 		$50K Buy
+12,500
New +$98.3K ﹤0.01% 1327

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

A.R.T. Advisors's XENE Position: Q3 2019 in Review

A.R.T. Advisors sold out of Xenon Pharmaceuticals (XENE) in Q3 2019, closing a stake of 10,760 shares — an estimated $106K sold.

A.R.T. Advisors first reported a position in XENE in Q1 2017 and held it in 4 quarters. The position peaked at $110K in Q2 2018. 54 funds tracked by Wall St. Rank hold XENE as of Q3 2019.

  • A.R.T. Advisors reported no remaining Xenon Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 10,760 Xenon Pharmaceuticals shares in Q3 2019, an estimated $106K.
  • A.R.T. Advisors first reported a position in Xenon Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • A.R.T. Advisors's Xenon Pharmaceuticals position peaked at $110K in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.